Pidotimod: A reappraisal

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 2, 2009, Pages 255-262

  Riboldi, Piersandro ^a   Gerosa, M ^a   Meroni, P L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Immunodeficiency; Innate immunity; Pidotimod; Recurrent infections

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; BETA LACTAM ANTIBIOTIC; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CONCANAVALIN A; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; HYDROCORTISONE; IMMUNOGLOBULIN A; INTERLEUKIN 2; METHOTREXATE; PHYTOHEMAGGLUTININ; PIDOTIMOD; PLACEBO; PREDNISONE; STEROID; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADD ON THERAPY; AGING; ALLERGIC ASTHMA; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; APOPTOSIS; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COXSACKIE VIRUS INFECTION; CYTOKINE RELEASE; DOSE RESPONSE; DOWN SYNDROME; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ESCHERICHIA COLI INFECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFECTION PREVENTION; INFLUENZA; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE INFECTION; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEUS INFECTION; PSEUDOMONAS INFECTION; RECURRENT INFECTION; RELAPSE; REVIEW; SENESCENCE; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THYMOCYTE; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 67650489213     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200201     Document Type: Review

References (33)

1. Coppi G, Falcone A, Manzardo S. Protective effects of pidotimod against experimental bacterial infections in mice. Arzneim Forsch Drug Res 1994; 44:1417-1421
2. Dianzani C, Colangelo D, Tonso E, Guidotto S, Viano I. In vivo antiviral effects of pidotimod. Arzneim Forsch Drug Res 1994; 44:1431-1433
3. Marelli P, Lupetti A, Senesi S, Uslenghi C, Girardello R, Campa M.. Potenziamento della resistenza alle infezioni virali e batteriche dopo somministrazione di pidotimod nel topo. Drugs Exp Clin Res 1993; XIX:15-21.
4. Taramelli D, Malabarba MG, Basilisco N, Sala G, Mattina R, Cocuzza C. Effects of pidotimod on macrophage functions in methylprednisolone-treated mice. Arzneim Forsch Drug Res 1994; 44:1425-1430
5. Migliorati G, Nicoletti I, Riccardi G. Immunomodulating activity of pidotimod Arzneim Forsch Drug Res 1994; 44:1421-1424
6. Coppi G, Manzanardo S. Experimental immunological screening test on pidotimod. Arzneim Forsch Drug Res 1994; 44:1411-1416
7. Chiarenza A, Iurato MP, Barbera N, Lempereur L, Cantarella G, Scapagnini U, Bernardini R. Modulating effects of the synthetic thymic dipeptide pidotimod on the immune system in the aging rat. Pharmacology and Toxicology 1994; 74:262-266 (Pubitemid 24154965)
8. Chiarenza A, Iurato MP, Barbera N, Lempereur L, Cantarella G, Scapagnini U, Scapagnini G, Bernardini R.. Effects of pidotimod on the immune and the neuroendocrine system in the aging rat. Arzneim Forsch Drug Res 1994; 44:1437-1440
9. Capsoni F, Minonzio F, Ongari AM, Girardello R, Di Bello M, Zanussi C. In vitro and ex vivo enhancement of neutrophil functions by PGT/1A, a new immunostimulating peptide. J Chemother 1991; 3:147-149
10. Caramia G, Clemente E, Solli R, Mei V, Cera R, Carnelli V, Venturosi V, Corsini A. Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children. Arzneim Forsch 1994; 44:1480-1484
11. Oddera S, Silvestri M, Sacco O, Eftimiadi C, Rossi G. Effetto del pidotimod sulla fagocitosi e sul killing intracellulare di Staphylococcus aureus da parte di polimorfonucleati neutrofili circolanti e di macrofagi alveolari umani. Drugs Exp Clin Res 1993; XIX:27-35.
12. Illeni MT, Bombelli G, Pattarino PL, Poli A. NK cell cytotoxic activity induced by a synthetic immunostimulant (pidotimod): an in vitro study. J Chemother 1991; 3:157-159
13. Pugliese A, Uslenghi C, Torre D, D'Alonzo L, Corgnati F, Girardello R.. Evaluation of the effect of pidotimod on the in vitro production of interferons. Int J Immunotherapy 1995; 11:71-76
14. Di Renzo M, Pasqui AL, Broni F, et al. The in vitro effect of pidotimod on some immune function in cancer patients. Immunopharm Immunot 1997; 19: 37-51. (Pubitemid 27112766)
15. Benetti GP, Fugazza L, Stramba Badiale M, Montalto F. Bombelli G, La Vecchia G, Illeni MT, Uslenghi C. Ex vivo evaluation of pidotimod activity on cell-mediated immunity. Arzneim Forsch Drug Res 1994; 44:1476-1479
16. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenger for an aging population. Immunology 2007; 120:435-446 (Pubitemid 46365019)
17. Borghi MO, Fain C, Barcellini W, Del Papa N, La Rosa L, Nicoletti F, Uslenghi C, Meroni PL. Ex vivo effect of pidotimod on peripheral blood mononuclear cell immune functions: study of an elderly population. Int J Immunotherapy 1994; 10:35-39 (Pubitemid 24124444)
18. Burgio GR, Marseglia GL, Severi F, Masarone M, Ottolenghi A, Pagliano L, Serra V, Nespoli L. Immunoactivation by pidotimod in children with recurrent respiratory infections. Arzneim Forsch Drug Res 1994; 44:1525-1529
19. Careddu P. Role of immunoactivation with pidotimod in recurrent respiratory infections in childhood. Arzneim Forsch Drug Res 1994; 44:1506-1511
20. Careddu P, Mei V, Venturosi V, Corsini A. Pidotimod in the treatment of recurrent respiratory infections in paediatric patients. Arzneim Forsch Drug Res 1994; 44:1485-1489
21. Clemente E, Solli R, Mei V, Cera R, Caramia G, Carnelli V, Ruffini E, Venturosi V, Corsini A. Therapeutic efficacy and safety of pidotimod in the treatment of urinary tract infections in children. Arzneim Forsch Drug Res 1994; 44:1490-1494
22. Aivasis V, Hatzimichail A, Papachristou A, Valeri R, Iuga-Donca G. Clinical evaluation and changes of the respiratory epithelium function after administration of pidotimod in Greek children with recurrent respiratory tract infections. Minerva Pediatr 2002; 54:345-349
23. Careddu P, Alfano S, Zavattini G. Pidotimod in the prophylaxis of recurrent acute tonsillitis in childhood. Adv Ther 1992; 9:174-183
24. Pozzi E, Dolcetti A, Orlandi O, Cirianni C, Moreo G, Piacenza G, Rampolla C, Scarpazza G. Pidotimod in the treatment of patients affected by bacterial exacerbations of chronic bronchitis. Arzneim Forsch Drug Res 1994; 44:1495-1498
25. Bisetti A, Ciappi G, Bariffi F, et al. Evaluation of the efficacy of pidotimod in the exacerbations in patients affected with chronic bronchitis Arzneim Forsch Drug Res 1994; 44:1499-1502
26. Ciaccia A and a multicenter study group. Pidotimod activity against chronic bronchitis exacerbation. Arzneim Forsch Drug Res 1994; 44:1516-1520
27. Cogo R, Ramponi A, Monzani G, Uslenghi C, Girardello R. Valutazione dell'attività di pidotimod sulla secrezione di IgA in pazienti affetti da BPCO. Gior It Allergol Immuno Clin 1993; 3:253-259
28. Vargas Correa JB, Espinosa Morales S, Bolanos Ancona JC, Faràn Ale JA.. Pidotimod en infeccion respiratoria récurrente en el nino con rinitis alérgica, asma o ambos padecimientos. Revista Alergia Mexico 2002; XLIX:27-30. (Pubitemid 34754947)
29. Auteri A, Pasqui AL, Gotti G, et al. The effect of a new biological response modifier (pidotimod) on surgery-associated immunodeficiency. Int J Immunother 1993; IX:95-102. (Pubitemid 23284826)
30. Annoni G, Poli A. Studio policentrico controllato sulla attività immunostimolante di PGT/1A nel paziente anziano con patologia internistica e chirurgica. NAM 1991; 7:45-52.
31. Cogo R, Furcolo F, Monzani GP. Studio clinico sull'acido timodolico nel trattamento delle infezioni delle vie respiratorie. NAM 1989; 5:492-497
32. La Mantia I, Grillo C, Mattina T, Zaccone P, Xiang M, Di Mauro M, Meroni PL, Nicoletti F. Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome J Chemother 1999; 11:126-130
33. Gourgiotis D, Papadopoulos NG, Bossios, A, Zamanis P, Saxoni-Papageorgiou P. Immune modulator pidotimod decreases the in vitro expression of CD30 in peripheral blood mononuclear cells of atopic asthmatic and normal children. J Asthma 2004; 41:285-287 (Pubitemid 38823310)